INTRODUCTION: Human papillomavirus (HPV) is an important risk factor for oropharyngeal cancer. Individuals with human immunodeficiency virus (HIV) have higher oral HPV prevalence but the risk factors for oral HPV infection are not well understood for either HIV-positive or HIV-negative individuals. METHODS: This study was nested within the Multicenter AIDS Cohort Study (MACS; men) and Women Interagency HIV Study (WIHS; women) cohorts. Exfoliated oral epithelial cells were collected from 379 HIV-positive and 266 at-risk HIV-negative individuals using a rinse and gargle with Scope mouthwash. Samples were tested for 36 types of HPV DNA using PGMY09/11 consensus primers and reverse line blot hybridization. Risk factors for oral HPV infection were explored using logistic regression with generalized estimating equations in this cross-sectional analysis. RESULTS: Prevalent oral HPV infection was common (34%), including HPV16 infection in 5.7% of participants. HIV-positive individuals had increased odds of prevalent oral HPV infection compared with HIV-negative individuals [adjusted OR = 2.1; 95% confidence interval (CI), 1.6-2.8]. Risk factors for prevalent oral HPV differed in HIV-positive and HIV-negative participants. Among HIV-negative individuals, higher number of recent oral sex or rimming partners were strong risk factors for prevalent oral HPV infection (each P(trend) < 0.01). In contrast, among HIV-positive individuals, lower CD4 T-cell count (P(trend) < 0.001) and higher number of lifetime sexual partners (P(trend) = 0.03) were strong risk factors. CONCLUSIONS: Oral HPV prevalence was elevated in HIV-positive individuals after controlling for differences in cigarette smoking and sexual behavior, supporting the possibility that HIV may affect the natural history of oral HPV. IMPACT: Immunosuppression may contribute to increased persistence or progression of oral HPV infection.
INTRODUCTION:Human papillomavirus (HPV) is an important risk factor for oropharyngeal cancer. Individuals with human immunodeficiency virus (HIV) have higher oral HPV prevalence but the risk factors for oral HPV infection are not well understood for either HIV-positive or HIV-negative individuals. METHODS: This study was nested within the Multicenter AIDS Cohort Study (MACS; men) and Women Interagency HIV Study (WIHS; women) cohorts. Exfoliated oral epithelial cells were collected from 379 HIV-positive and 266 at-risk HIV-negative individuals using a rinse and gargle with Scope mouthwash. Samples were tested for 36 types of HPV DNA using PGMY09/11 consensus primers and reverse line blot hybridization. Risk factors for oral HPV infection were explored using logistic regression with generalized estimating equations in this cross-sectional analysis. RESULTS: Prevalent oral HPV infection was common (34%), including HPV16 infection in 5.7% of participants. HIV-positive individuals had increased odds of prevalent oral HPV infection compared with HIV-negative individuals [adjusted OR = 2.1; 95% confidence interval (CI), 1.6-2.8]. Risk factors for prevalent oral HPV differed in HIV-positive and HIV-negative participants. Among HIV-negative individuals, higher number of recent oral sex or rimming partners were strong risk factors for prevalent oral HPV infection (each P(trend) < 0.01). In contrast, among HIV-positive individuals, lower CD4 T-cell count (P(trend) < 0.001) and higher number of lifetime sexual partners (P(trend) = 0.03) were strong risk factors. CONCLUSIONS: Oral HPV prevalence was elevated in HIV-positive individuals after controlling for differences in cigarette smoking and sexual behavior, supporting the possibility that HIV may affect the natural history of oral HPV. IMPACT: Immunosuppression may contribute to increased persistence or progression of oral HPV infection.
Authors: Anthony J Silvestre; John B Hylton; Lisette M Johnson; Carmoncelia Houston; Mallory Witt; Lisa Jacobson; David Ostrow Journal: Am J Public Health Date: 2006-05-02 Impact factor: 9.308
Authors: Jennifer E Cameron; Donald Mercante; Megan O'Brien; Ann M Gaffga; Janet E Leigh; Paul L Fidel; Michael E Hagensee Journal: Sex Transm Dis Date: 2005-11 Impact factor: 2.830
Authors: T E Wilson; L S Massad; K A Riester; S Barkan; J Richardson; M Young; A Gurtman; R Greenblatt Journal: AIDS Date: 1999-04-01 Impact factor: 4.177
Authors: Aimée R Kreimer; Rohini K Bhatia; Andrea L Messeguer; Paula González; Rolando Herrero; Anna R Giuliano Journal: Sex Transm Dis Date: 2010-06 Impact factor: 2.830
Authors: Amanda J Durante; Ann B Williams; Maria Da Costa; Teresa M Darragh; Kaveh Khoshnood; Joel M Palefsky Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-07 Impact factor: 4.254
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Gypsyamber D'Souza; Neil D Gross; Sara I Pai; Robert Haddad; Karen S Anderson; Shirani Rajan; Jennifer Gerber; Maura L Gillison; Marshall R Posner Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza Journal: Am J Epidemiol Date: 2014-12-04 Impact factor: 4.897